Implementation of a Hematology Outpatient Sepsis Alert Protocol

As quality measures are set by governing bodies to reflect reimbursement, institutions are becoming not only fiscally responsible, but at the same time improving quality of care. Newer and advanced treatments come with increased cost and unique side effects that can be challenging for both patients and providers. Infections are among the most common noncancer causes of death among patients with hematologic malignancies. Patient education plays a critical part in symptom management and quality of life. Quality initiatives directed at standardized clinical pathways for symptom management, and development for urgent cancer care tactics are becoming a standard in cancer care to help reduce sepsis and the need for acute care.

Target Audience

This program is designed to meet the educational needs of hematology/oncology nurses and nurse practitioners who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss the steps involved to create a system of early recognition of sepsis in an outpatient hematology clinic. 
  • Explain the tools and resources that could be used for standardized educational pathways to help identify patients at risk for sepsis. 
  • Review how implementation of sepsis protocols and data obtained impact quality, cost and patient satisfaction.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Kite, A Gilead Company
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

This activity is supported by an independent medical education grant from Pfizer Inc. 

This activity is supported by an independent educational grant from Incyte Corporation.

Course summary
Available credit: 
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
12/15/2022
Course expires: 
12/15/2023
Cost:
$0.00

Shelly Brown, MS, APRN-CNS, OCN, AOCNS
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Shelly Brown, MS, APRN-CNS, OCN, AOCNS

NCCN Staff Disclosures 

The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Samantha L. Tamburro, RN, BSN, CPON
Flatiron Health, Inc.: Salary

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour.

Available Credit

  • 0.75 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing